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Cancer Biology and Signal Transduction
BRCA2 andRAD51 Promote Double-Strand Break Formation
and Cell Death in Response to Gemcitabine
Rebecca M. Jones1, Panagiotis Kotsantis1, Grant S. Stewart1, Petra Groth2, and Eva Petermann1
Abstract
Replication inhibitors cause replication fork stalling and double-strand breaks (DSB) that result from
processing of stalled forks. During recovery from replication blocks, the homologous recombination (HR)
factor RAD51mediates fork restart andDSB repair.HRdefects therefore sensitize cells to replication inhibitors,
with clear implications for cancer therapy. Gemcitabine is a potent replication inhibitor used to treat cancers
with mutations in HR genes such as BRCA2. Here, we investigate why, paradoxically, mutations in HR genes
protect cells fromkilling by gemcitabine. UsingDNAreplication andDNAdamage assays inmammalian cells,
we show that even short gemcitabine treatments cause persistent replication inhibition. BRCA2 andRAD51 are
recruited to chromatin early after removal of the drug, actively inhibit replication fork progression, and
promote the formation ofMUS81- andXPF-dependentDSBs that remain unrepaired.Our data suggest thatHR
intermediates formed at gemcitabine-stalled forks are converted intoDSBs and thus contribute to gemcitabine-
induced cell death, which could have implications for the treatment response of HR-deficient tumors.
Mol Cancer Ther; 13(10); 2412–21. 2014 AACR.
Introduction
Many cytotoxic anticancer treatments target prolifer-
ating cells by interfering with DNA replication, thus
generating lethal DNA damage. Such treatments exploit
the high proliferation rates of cancer cells, and can be
further potentiated by cancer-specific defects in DNA
repair (1). The mechanisms of action of two replication
inhibitors, the ribonucleotide reductase (RNR) inhibitor
hydroxyurea (HU) and the DNA polymerase inhibitor
aphidicolin, have been studied in detail. Both cause
slowing or stalling of replication forks, generating exces-
sive amounts of ssDNA as DNA polymerases stall but
the replicative helicase continues to unwind DNA. Rep-
lication inhibition activates the ATR-dependent S-phase
checkpoint, which stabilizes stalled forks and downre-
gulates new replication initiation (origin firing) to pre-
vent further damage (2). After removal of the inhibitor,
replication restarts and the checkpoint is inactivated.
Depending on the length of treatment, restart occurs
either by resumption of replication fork progression or
through new origin firing (2, 3). After a few hours of
replication block, structure-specific nucleases such as
MUS81-EME1 begin to process the stalled forks into
double-strand breaks (DSB; refs. 3, 4). Accumulation of
these DSBs creates a requirement for the DSB repair
pathways homologous recombination (HR) and nonho-
mologous end joining (NHEJ) for cellular resistance to
replication inhibitors (5). HR depends on the recombi-
nase RAD51 and mediator proteins such as XRCC3 and
BRCA2, which promote the loading of RAD51 onto
ssDNA. In addition to their roles in DSB repair, BRCA2
and RAD51 also prevent excessive MRE11-dependent
resection of the daughter strands at stalled forks (6, 7)
and RAD51 promotes restart of stalled forks after release
from HU (3). All of these findings are of potential clinical
importance as several types of cancer can have genetic
defects in HR. This includes breast and pancreatic cancer,
where familial and sporadic forms can display inactivat-
ing mutations or promoter methylations in BRCA1,
BRCA2, PALB2, BRIP1, and other genes of the Fanconi
Anemia pathway (8–11). Breast and pancreatic cancer are
treated with the replication inhibitor gemcitabine (20,20-
difluorodeoxycytidine). In the cells, gemcitabine is con-
verted into its di- and triphosphates, which inactivate
RNR and inhibit DNA polymerase after incorporation
into nascent DNA (12). This strongly inhibits DNA syn-
thesis and causes p53-independent apoptosis. The cyto-
toxic DNA lesions induced by gemcitabine and the DNA
repair pathways that respond to them are poorly under-
stood. Intriguingly, previous studies found that Chinese
hamster cells mutated in BRCA2 or another HRmediator,
XRCC3, and the FANCC-mutated pancreatic cancer cell
line PL11 were less sensitive to gemcitabine treatments
than their HR-proficient counterparts (13–15).
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Here, we investigate the molecular mechanism by
which the HR factors BRCA2 and RAD51 promote gem-
citabine-induced cell death. Our data suggest that even
after short gemcitabine treatments, replication forks
remain stalled and are converted into DSBs that persist
in the cells. BRCA2andRAD51 are recruited to chromatin,
inhibit fork progression, and promote the formation of
DSBs that are dependent on the structure-specific endo-
nucleases MUS81 and XPF. Our data suggest that HR
intermediates formed at stalled forks promote gemcita-
bine cytotoxicity, which could have implications for the
treatment response of HR-deficient tumors.
Materials and Methods
Cell lines and reagents
Human cell lines were all obtained from ATCC more
than 2years ago andwere therefore authenticated using 8-
locus short tandem repeat profiling (LGC standards).
Human U2OS osteosarcoma cells were last authenticated
in April 2013. H1299 lung carcinoma cells were last
authenticated in March 2011 and have not been cultured
since. BxPC3 pancreatic adenocarcinoma cells, MCF7
breast cancer cells, and OVCAR3 human ovarian cancer
cells were last authenticated in April 2014.
VC8 and VC8-B2 cells were obtained from Małgorzata
Z. Zdzienicka (16, authentication not available). Cells
were confirmed mycoplasma-free and grown in DMEM
with 10% FCS in a humidified atmosphere containing 5%
CO2. OVCAR3 cells were grown in DMEMwith 10% FBS,
0.01 mg/mL insulin, and 1% nonessential amino acids
(Sigma). Gemcitabine (Tocris Bioscience) was used at 2 or
5 mmol/L for 2 hours. DNA-PK inhibitor NU7441 (Tocris
Bioscience) was used at 1 mmol/L. BLM inhibitor ML216
(Sigma-Aldrich) was used at 1.8 mmol/L as previously
described (17).
DNA fiber analysis
Cellswere labeledwith 25mmol/LCldUand 250mmol/
L IdU as indicated. For release from gemcitabine, cells
were washed three times with warm PBS. Controls were
labeledwithCldUand IdU for 20minutes each.DNAfiber
spreadswere prepared as described (3). Acid-treated fiber
spreadswere incubatedwith rat anti-BrdU (detects CldU,
BU1/75; AbD Serotec) andmouse anti-BrdU (detects IdU,
B44; Becton Dickinson) for 1 hour. Slides were fixed with
4% formaldehyde and incubated with anti-rat IgG Alexa-
Fluor 555 and anti-mouse IgG AlexaFluor 488 (Molecular
Probes) for 1.5 hour. Images were acquired on an E600
Nikon microscope using a Plan Apo 60 (1.3NA) oil lens
(Nikon), a digital camera (C4742-95; Hamamatsu) and the
Volocity acquisition software (PerkinElmer). Imageswere
analyzed using ImageJ (http://rsbweb.nih.gov/ij/). For
quantification of replication structures, 60 to 250 struc-
tures were counted per independent experiment.
Immunofluorescence
For phospho-Histone H2AX, 53BP1, Lamin B, and
phospho-Histone H3, cells were fixed with 4% formalde-
hyde and permeabilized with 0.2% Triton X-100 for 5
minutes. For RAD51 foci, cells were pre-extracted with
0.2% Triton X-100 for 1 minute. For colocalization with
replication foci, antibodies were fixed with 4% formalde-
hyde before DNA denaturation with HCl and immunos-
taining for thymidine analogues. Primary antibodieswere
ratmonoclonal anti-BrdU (BU1/75,AbDSerotec, 1:400) to
detect CldU, mouse monoclonal anti-BrdU (B44, Becton
Dickinson, 1:50) to detect IdU, mouse monoclonal anti-
phospho-Histone H2AX (Ser139; JBW301, Merck Milli-
pore, 1:1000), rabbit polyclonal anti-RAD51 (H-92, Santa
Cruz Biotechnology, 1:500), rabbit polyclonal anti-53BP1
(Bethyl, 1:3000), goat polyclonal anti-Lamin B (Santa Cruz
Biotechnology, 1:400), and rabbit polyclonal anti-phos-
pho-Histone H3 (Ser10; Merck Millipore, 1:500). Second-
ary antibodies were anti-Rat IgG AlexaFluor 555, anti-
mouse IgG AlexaFluor 488, anti-rabbit IgG AlexaFluor
555, or AlexaFluor 647 and anti-goat IgG Alexafluor 594
(Molecular Probes). DNA was counterstained with 4´,6-
diamidino-2-phenylindole dihydrochloride (DAPI) and
images acquired as above.
Cell survival assays
For clonogenic survival, defined numbers of cells were
plated before treatment with gemcitabine (0.1–5 mmol/L)
for 2 hours. Colonies of >50 cells were allowed to form in
fresh medium, fixed and stained with 50% ethanol, 2%
methylene blue for 10 minutes. Apoptosis was quantified
by counting fragmented nuclei after DAPI staining and
mitotic catastrophe was quantified by counting fragmen-
ted nuclei displaying Lamin B staining.
Flow cytometry
A total of 5  105 cells per sample were treated as
indicated, harvested and fixed with cold 70% ethanol
before staining with propidium iodide (10 mg/mL).
Cell-cycle profiles were gathered using the C6 Flow Cyt-
ometer system (Accuri) and analyzed with CFlow Plus.
Pulsed-field gel electrophoresis
A total of 2  106 cells per sample were treated as
indicated, harvested, and melted into 1.0% InCert-Aga-
rose (Lonza) inserts. Inserts were digested in 0.5 mol/L
EDTA-1% N-laurylsarcosyl-proteinase K (1 mg/mL) at
room temperature for 48 hours andwashed three times in
Tris-EDTA (TE) buffer. Inserts were loaded onto a sepa-
ration gel (1.0% chromosomal-grade agarose; Bio-Rad).
Separation was performed using a CHEF DR III (Bio-Rad;
120-field angle, 240-second switch time, 4 V/cm1, 14C)
for 20 hours. Images of ethidium bromide-stained gels
were acquired using a Syngene G:BOX gel imaging sys-
tem. DSBs (chromosome fragments >2 Mbp) were quan-
tified by densitometry using ImageJ. Intensity of DNA
entering the gelwasnormalized to totalDNAanduntreat-
ed control was subtracted to obtain final values.
siRNA treatment
siRNAagainst humanRAD51 (14),MUS81 (siGENOME
SMARTpoolD-016143), andXPF(ERCC4;OnTARGETplus
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SMARTpool L-019946-00) were from Thermo Fisher. "All-
stars negative control siRNA" (nonT) was from Qiagen.
Cells were transfected with 50 nmol/L of each siRNA
using Dharmafect 1 (Thermo Fisher) for 24, 48 (RAD51),
or 72 hours (XPF and MUS81) before treatment with
gemcitabine.
Western blotting
Primary antibodies were rabbit polyclonal anti-
RAD51 (H-92, Santa Cruz Biotechnology, 1:500), mouse
monoclonal anti-MUS81 (MTA30 2G10/3, Santa Cruz
Biotechnology, 1:500), mouse monoclonal anti-XPF (219,
Fisher Scientific, 1:200), mouse anti-aTubulin (B512,
Sigma, 1:5,000), rabbit polyclonal anti–b-actin (Cell Sig-
naling Technology, 1:1,000), and mouse monoclonal
anti-PARP1 (F-2, Santa Cruz Biotechnology, 1:500). For
further antibody information, see Supplementary Mate-
rials and Methods.
Statistical analysis
The mean and 1 SEM of independent repeats are
shown. Statistical significance was determined using the
Student t test (, P < 0.05; , P < 0.01; , P < 0.001).
Results
We used BRCA2-mutated VC8 and BRCA2-comple-
mented VC8-B2 Chinese hamster fibroblasts (p53 mutat-
ed), an isogenic model for BRCA2 function that has
successfully been used to study the role of BRCA2 in
chemotherapy response (18).We tested short gemcitabine
treatments in the micromolar range, similar to clinically
relevant concentrations (19, 20). Although VC8 cells were
hypersensitive to cisplatin as expected (Supplementary
Fig. S1A), they were less sensitive than VC8-B2 cells to
higher concentrations of gemcitabine (Fig. 1A). Similar
results were obtained after siRNA-depleting RAD51 in
human U2OS osteosarcoma and BxPC3 pancreatic cancer
cell lines (both p53wild-type), suggesting that thiswas not
due to secondary mutations acquired in VC8 cells, but to
loss of RAD51 function (Fig. 1B andC and Supplementary
Fig. S1B).
We initially used 2 mmol/L gemcitabine, which has
been shown to inhibit fork progression and allowed
about 50% survival in our cell lines, and measured
replication restart using DNA fiber analyses (Fig. 1D).
Even at this low concentration, most forks remained
stalled and did not resume progression for at least 24
hours after release from 2 hour gemcitabine (Fig. 1D).
Levels of fork stalling were comparable between
BRCA2-proficient and -deficient cells and similar
results were obtained using RAD51-depleted U2OS
cells (Fig. 1E and F). Levels of phospho-S139-H2AX
(gH2AX), a marker of stalled forks (3), increased after
gemcitabine release and remained high for at least 72
hours, suggesting that stalled forks persisted for several
days (Fig. 1G and H). The induction of gH2AX was
comparable in BRCA2-proficient and -deficient as well
as control- and RAD51-depleted cells (Fig. 1G and H).
However, BRCA2-deficient cells displayed lower
gH2AX staining after 72 hours release, suggesting a
quicker recovery from gemcitabine-induced DNA dam-
age (Fig. 1G). Overall these data did not suggest that
promotion of fork restart by BRCA2 or RAD51 plays a
role in response to cytotoxic gemcitabine treatments.
Despite persistent fork stalling, cells resumed replica-
tion between 6-hour and 24-hour release, firing new
origins and resuming slow progression through S phase
(Fig. 2A and B). Nevertheless, markers of S-phase check-
point signaling remained active during replication restart
(Supplementary Fig. S2). Cell-cycle progression was
accompanied by apoptosis and mitotic catastrophe (MC),
which peaked after 2 to 3 days release (Fig. 2B and C). The
appearance ofMC suggests that some cell death did result
from aberrant mitotic entry in presence of unrepaired
DNA damage (21). VC8 cells displayed lower induction
ofMCandapoptosis after 5mmol/Lgemcitabine (Fig. 2D),
which was not due to VC8 cells being prevented from
cycling and mitotic entry. Instead, VC8 cells displayed
higher percentages of cells positive for phospho-histone
H3 (Fig. 2E) and faster progression into the next G1 phase
1 day after release compared with VC8-B2 cells (Fig. 2F).
Initial accumulation in S phase was also not lower in
BRCA2-deficient cells (Fig. 2F), confirming that reduced
gemcitabine sensitivitywasnot due to fewer cells entering
S phase. Interestingly, VC8 cells displayed fewer gH2AX-
positive cells and a lower percentage of S-phase cells at 3
days after release, suggesting a quicker recovery from
gemcitabine in absence of BRCA2 (Fig. 1G and 2F).
Wedecided to further investigate the role of BRCA2and
RAD51 at gemcitabine-stalled replication forks. In addi-
tion to promoting fork restart, RAD51 and BRCA2 also
prevent shortening of daughter strands at stalled forks
(6, 7), and RAD51 inhibits fork progression during cis-
platin and camptothecin treatments (22, 23). To investi-
gate if either of these processes occurs after release from
gemcitabine, we compared the length of DNA replicated
during 2-hour gemcitabine treatment and after 4-hour
release from 5 mmol/L gemcitabine in VC8 and VC8-B2
cells (Fig. 3A). Tracks replicated during the 2-hour gem-
citabine treatment were longer in presence of BRCA2, as
has been described before (6). However, after release
from gemcitabine, replicated tracks in BRCA2-proficient
cells remained the same length,whereas tracks in BRCA2-
deficient cells further increased in length, suggesting that
some forks were still progressing (Fig. 3B, C, and F).
Similar results were obtained using RAD51-depleted
U2OS cells (Fig. 3D, E, and G). Our data suggest that after
release from gemcitabine, BRCA2 and RAD51 are
recruited to forks where RAD51 promotes transactions
that inhibit further fork progression. In HR-proficient
cells, RAD51 foci indeed accumulated and persisted for
72 hours after release (Fig. 3H and I), suggesting that HR
was initiated but not completed during that time.
Next,we testedwhether gemcitabine-stalled forkswere
processed into DSBs. We first measured accumulation of
Jones et al.
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nuclear 53BP1 foci, which mark sites of DSBs (24). High
numbers of 53BP1 foci that colocalized with replication
foci accumulated after 2- and 16-hour release in U2OS
and VC8-B2 cells, respectively (Fig. 4A and B). Com-
pared with gH2AX foci (Fig. 1G and H), 53BP1 foci
formation was delayed and only around half of
gH2AX-positive cells also contained 53BP1 foci. This
supports the idea that gH2AX marks all stalled repli-
cation forks as well as DSBs, whereas 53BP1 only accu-
mulates at the subset of forks that have been processed
into DSBs. Pulsed-field gel electrophoresis (PFGE) of
genomic DNA confirmed that the increase in 53BP1 foci
correlated with an increase in DSB levels (Fig. 4C and
Supplementary Fig. S3A). As with RAD51 foci, DSB
levels remained high for 2 to 3 days after release,
suggesting that little DSB repair was occurring.
As DSBs are highly toxic DNA lesions and likely to
contribute to gemcitabine toxicity, we next analyzed
Figure 1. HR defects protect from cell death, but have no effect on irreversible replication fork stalling after release from gemcitabine. A, clonogenic survival of
VC8 (BRCA2) andVC8-B2 (þBRCA2) cells treatedwithgemcitabine for 2 hours and released into freshmedium.B, clonogenic survival ofU2OScellsRAD51
treated as in A. C, protein levels of RAD51 and PARP1 (loading control) in U2OS cells 24 hours after transfection with RAD51 or nonT siRNA. D, schematic and
representative images for DNA ﬁber labeling. CldU-only labeled tracks (stalled forks) were normalized to all CldU-containing tracks. Bars, 10 mm. E,
quantiﬁcation of stalled forks in VC8 and VC8-B2 cells (asterisks comparedwithCon). F, quantiﬁcation of stalled forks in U2OScellsRAD51 siRNA (asterisks
comparedwithCon). G, percentagesof cells displayingmore than 10 gH2AX foci after release fromgemcitabine.H, percentages ofU2OScellsRAD51 siRNA
displaying more than 10 gH2AX foci after release from gemcitabine. Error bars, SEM; , P < 0.05; , P < 0.01; , P < 0.001, Student t test.
BRCA2 and Gemcitabine
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whether gemcitabine-induced DSB formation depended
on BRCA2 and RAD51. Indeed, PFGE showed that
although VC8 cells displayed higher background levels
of unrepaired DSBs, the additional increase in DSBs after
gemcitabinewas higher in the presence of BRCA2 (Fig. 4D
and E and Supplementary Fig. S3B). Similarly, RAD51-
depleted U2OS cells accumulated fewer 53BP1 foci than
control cells after release from gemcitabine (Fig. 4F–H).
Comparable results were obtained in RAD51-depleted
human cancer cell lines derived from pancreatic (BxPC3,
p53wild-type), breast (MCF7, p53wild-type), and ovarian
cancer (OVCAR3, p53 mutated; Supplementary Figs. S4–
S6). HR-deficient cells thus accumulate fewer DSBs after
gemcitabine treatment.
In addition to HR, NHEJ acts as an alternative and
competing repair pathway for DSBs. AlthoughNHEJmay
notbeable to faithfully repair one-endedDSBsat collapsed
replication forks, it can promote resistance to replication
inhibitors such as HU, suggesting that some replication-
dependent breaks are substrates for NHEJ (5). We consid-
ered that reduced gemcitabine sensitivity in HR-deficient
cells might result from DSBs being more efficiently
repaired by NHEJ in absence of HR. We inhibited NHEJ
using DNA-PK inhibitor NU7441 to test whether this
could sensitize HR-deficient cells to gemcitabine. NU7441
alone increased the background levels of unrepairedDSBs
(Supplementary Fig. S3B). However, cotreatment with
NU7441 did not increase gemcitabine toxicity (Fig. 5A) or
gemcitabine-induced DSB levels in BRCA2-deficient cells
(Fig. 5B and Supplementary Fig. S3B). In contrast, BRCA2-
proficient cells treated with NU7441 were more sensitive
to gemcitabine and accumulated more DSBs early after
release from gemcitabine (Fig. 5A and B), suggesting that
some BRCA2-dependent DSBs are repaired by NHEJ.
To further support a role forHR ingemcitabine-induced
DSB formation and cell death, we used a small-molecule
inhibitor of the BLM helicase, ML216 (17). BLM counter-
actsRAD51 function in the initiationofHRby resolvingD-
loop structures (25). If RAD51-mediatedHR is responsible
for gemcitabine-induced DSBs and cell death, then BLM
inhibition should exacerbate both DSB formation and cell
death. Indeed, we observed a small but reproducible
increase in DSBs and cell death in cells treated with BLM
inhibitor (Fig. 5C and D).
Finally, we used siRNA depletion in U2OS cells to test
which enzymes were responsible for converting stalled
Figure 2. BRCA2-deﬁcient and
-proﬁcient cells display aberrant
cell-cycle progression after release
from gemcitabine. A, new origin
ﬁring in VC8 and VC8-B2 cells after
release from gemcitabine. DNA
ﬁber labeling was performed as
in Fig. 1D and IdU-only labeled
tracks (new origins) were
normalized to all CldU-containing
tracks. B, FACS analysis of cell-
cycle progression and time course
of mitotic catastrophe (MC) and
apoptosis in VC8-B2 cells after
release from gemcitabine. C,
representative images of
DAPI- and Lamin B1-stained VC8-
B2 cells withmitotic catastrophe or
apoptotic phenotypes after 48-
hour release from gemcitabine.
Bars, 10 mm. D, increase inMC and
apoptosis in VC8 and VC8-B2 cells
after release from 5 mmol/L
gemcitabine. E, percentages of
VC8-B2 and VC8 cells positive for
phospho-histone H3 staining
following release from gemcitabine
in the presence of 1.5 mmol/L
nocodazole. F, cell-cycle
progression in VC8 and VC8-B2
cells after release from 5 mmol/L
gemcitabine for 24 to 72 hours.
Error bars, SEM; , P < 0.01,
Student t test.
Jones et al.
Mol Cancer Ther; 13(10) October 2014 Molecular Cancer Therapeutics2416
on November 18, 2014. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Published OnlineFirst July 22, 2014; DOI: 10.1158/1535-7163.MCT-13-0862 
forks into DSBs, focusing on the MUS81-EME1 and XPF-
ERCC1 structure–specific endonucleases. In vitro, only
MUS81-EME1 cleaves stalled replication fork structures,
but in vivo XPF-ERCC1 and MUS81-EME1 can act in
parallel pathways to process joint molecule recombina-
tion intermediates such as Holliday junctions (26, 27).
Cells were transfected with XPF or MUS81 siRNA for
72 hours, treated with 5 mmol/L gemcitabine for 2 hours,
and released for up to 72 hours. Proteins remained deplet-
ed for at least 2days after treatment (Fig. 6A–C).Depletion
ofMUS81orXPFcouldprevent gemcitabine-inducedDSB
formation, with codepletion of both proteins being more
effective (Fig. 6DandE).DSBs in gemcitabine-treated cells
thus depend on BRCA2 and RAD51, and therefore likely
on RAD51 loading and filament formation for the initia-
tion of HR, and on endonucleases that cleave HR inter-
mediates. These data suggest that these DSBs arise not
only simply through endonucleolytic cleavage of stalled
Figure 3. BRCA2 and RAD51 inhibit
replication fork progression after
release from gemcitabine. A,
labeling protocol for DNA ﬁber
analyses. Cells were labeled with
CldU, treated with IdU and 5 mmol/
L gemcitabine for 2 hours and
released into IdU for 4 hours. B,
length distributions of IdU-labeled
tracks from VC8-B2 cells
(þBRCA2). C, length distributions
of IdU-labeled tracks from VC8
cells (BRCA2). D, length
distributions of IdU-labeled tracks
from U2OS cells treated with nonT
siRNA. E, length distributions of
IdU-labeled tracks fromU2OScells
treated with RAD51 siRNA. F,
average lengths of IdU tracks in
VC8 and VC8-B2 cells treated as in
A. G, average lengths of IdU tracks
in U2OS cells  RAD51. H,
representative images of RAD51
foci in cells released from 5 mmol/L
gemcitabine for 24 hours. I,
percentages of cells displaying
more than 5 RAD51 foci during 1
and 2 hours gemcitabine treatment
and after release from gemcitabine
(asterisks compared with Con).
Error bars, SEM; , P < 0.05;
, P < 0.01, Student t test.
BRCA2 and Gemcitabine
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replication forks, but also through processing of recom-
bination intermediates.
Discussion
We report that after release from gemcitabine treat-
ment, BRCA2 andRAD51 inhibit replication fork progres-
sion, promote MUS81/XPF-dependent DSB formation,
and exacerbate cell death. This supports the idea that
initiation of HR is required for DNA damage formation
at gemcitabine-stalled replication forks. HR, normally a
pathway that prevents accumulationofDNAdamage, can
thus promote the formation of DNA damage after gemci-
tabine treatment.
We speculate that in response to gemcitabine, BRCA2-
assisted loading of RAD51 onto replication forks pro-
motes the generation of HR intermediates, which inhibit
further fork progression. This is likely the same mech-
anism as the RAD51-mediated fork slowing previously
observed in cisplatin- or camptothecin-treated cells (22,
23), although the cellular consequences of this phenom-
enon have not been described. We speculate that these
HR intermediates, likely D-loops and Holliday junc-
tions, present substrates for endonucleolytic processing
Figure 4. Gemcitabine causes
DSBs that depend on BRCA2 and
RAD51. A, 53BP1 foci (far-red) and
colocalization with replication foci
(CldU, red and IdU, green) in VC8-
B2 cells 6 hours after release from2
mmol/L gemcitabine. Bars, 10 mm.
B, percentages of cells displaying
more than 10 53BP1 foci after
release from gemcitabine
(asterisks compared with Con). C,
PFGE showing DSB induction after
release from 2 mmol/L gemcitabine
in U2OS and VC8-B2 cells (see
Supplementary Fig. S3A for
quantiﬁcation). D, PFGE of DSB
induction in VC8-B2 and VC8 cells
after release from 5 mmol/L
gemcitabine (cropped lanes are
from one gel, see Supplementary
Fig. S3B). E, percentages of DNA
released from plugs in DSB in VC8-
B2 and VC8 cells. F, outline of
experimental design for 53BP1 foci
quantiﬁcation. Twenty-four hours
after transfection with RAD51 or
nonT siRNA, U2OS cells were
treated with 5 mmol/L gemcitabine
for 2 hours, released for the times
indicated, ﬁxed and stained for
53BP1. G, representative images
of 53BP1 foci in U2OS cells 
RAD51 siRNA released from 5
mmol/L gemcitabine. Bar, 10mm.H,
percentages of U2OS cells 
RAD51siRNAdisplayingmore than
10 53BP1 foci after release from 5
mmol/L gemcitabine. Error bars,
SEM; , P < 0.05; , P < 0.01;
, P < 0.001, Student t test.
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by MUS81 and XPF to generate DSBs (Fig. 6F). Gemci-
tabine-induced DSBs are not efficiently repaired, which
could explain why HR does not protect from cell death.
We speculate that the processes described here also
occur at forks that have been stalled by other types of
replication inhibitors, but this may not be obvious if the
inhibitor also induces DSBs by other mechanisms and
does not prevent HR-mediated DSB repair. Our data
suggest that for transient treatments, DNA damage
response factors that promote rearrangements and
nuclease processing of stalled forks can be expected to
cause sensitivity to gemcitabine (Fanconi Anemia pro-
teins, BRCA2, XRCC3, RAD51), whereas factors
involved in later steps of DSB repair should promote
survival or have little effect (DNA Ligase IV, RAD54).
Our data also suggest that the very persistent effects of
even short exposures to gemcitabine are important for its
cytotoxic action. Gemcitabine inactivates RNR irrevers-
ibly and gemcitabine nucleotides accumulate in cells after
treatment (12), which likely underlies the prolonged rep-
lication inhibition observed. After release from gemcita-
bine, stalled replication forks andDNAdamage signaling
therefore persist, but cannot prevent the eventual resump-
tion of cell-cycle progression. A similar phenomenon has
been observed during prolonged HU treatments and
couldbe common to all situations of prolonged replication
fork stalling (4, 28). This cell-cycle progression in presence
of unresolved DNA lesions contributes to cell death by
mitotic catastrophe and likely also to DSB formation and
apoptosis, as mitotic CDK1 activity has been suggested to
promote MUS81-dependent DSB formation at perturbed
forks (29).
These peculiarities of transient gemcitabine treat-
ments could explain why reports on the impact of HR
status on gemcitabine sensitivity are still conflicting.
Previous studies have variously used continuous or
transient treatments. For example, RAD51 depletion
sensitizes cells to continuous treatment with low doses
of gemcitabine (30, 31), but both RAD51 depletion and
mutations in BRCA2 decrease sensitivity when com-
bined with transient treatments at higher doses, which
seem more relevant for clinical applications (15 and this
study). Indeed, a recent study showed that ATR and
CHK1 inhibitors could sensitize ovarian cancer cells to
transient but not to continuous gemcitabine treatments
(32). As ATR and CHK1 protect stalled forks from DSB
formation, this suggests that the danger of DSB is higher
after release from gemcitabine than during continuous
treatment, possibly due to increased cell-cycle progres-
sion. In agreement with this, our preliminary data
suggest that more DSBs can be detected after release
from transient gemcitabine treatment compared with
continuous treatment for the same time (Supplementary
Fig. S7). On the other hand, mutations in the HR genes
XRCC3 and FANCC can promote resistance even to
continuous gemcitabine treatments (13, 14). This sug-
gests that more research into the time course of gemci-
tabine action is needed, especially as this information
could be crucial for optimal scheduling in combination
treatments such as gemcitabine/carboplatin.
Figure 5. Roles of NHEJ and
BLM helicase in the response to
gemcitabine. A, clonogenic
survival of VC8-B2 and VC8 cells
treated with gemcitabine and 1
mmol/L NU7441 for 2 hours and
released into fresh medium
containing 1 mmol/L NU7441,
compared with survival without
NU7441 (Fig. 1A). B, percentages
of DNA released from plugs in DSB
in VC8-B2 and VC8 cells released
from treatment with 5 mmol/L
gemcitabine in presence or
absence of 1 mmol/L NU7441 (see
Supplementary Fig. S3B for gel).
Error bars, SD. C, percentages of
U2OS cells  BLM inhibitor
displayingmore than1053BP1 foci
after release from 5 mmol/L
gemcitabine. Cells were
preincubated with 1.8 mmol/L
BLM inhibitor for 1 hour before
gemcitabine treatment and
released in fresh medium
containing BLM inhibitor. D,
clonogenic survival of U2OS cells
 BLM inhibitor treated with
gemcitabine for 2 hours as in C.
Error bars, SEM; , P < 0.05;
, P < 0.01; , P < 0.001,
Student t test.
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There are three published case studies of patients with
pancreatic cancer carrying BRCA2 or PALB2 mutations
that did not respond or responded poorly to gemcita-
bine, but responded well to a subsequent treatment with
the crosslinking agents cisplatin or mitomycin C (33–35).
Although we do not consider these data evidence that
HR-deficient pancreatic cancers are more resistant to
gemcitabine than other pancreatic cancers, they do show
that cancers that have proven resistant to one DNA-
damaging agent (gemcitabine) can be hypersensitive
to a different DNA-damaging agent (e.g., carboplatin).
This also suggests that in the case of gemcitabine/plat-
inum combination therapies, the hypersensitivity of
HR-deficient tumors to platinum compounds could
compensate for any gemcitabine resistance in these
tumors.
Taken together, our data have potential implications for
the scheduling of gemcitabine combination treatments in
general and pose the question as to whether HR-deficient
tumors would respond well to single-agent gemcitabine
treatments.
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